Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).

Sonja Zweegman,Saad Z. Usmani,Katherine Chastain,Jodi Carey,Karen Ren,Elena Smith,Maria Krevvata,Jianping Wang,Jessica Vermeulen,Thierry Facon

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).

2019

Sonja Zweegman
Saad Z. Usmani
Katherine Chastain
Jodi Carey
Karen Ren
Elena Smith
Maria Krevvata
Jianping Wang
Jessica Vermeulen
Thierry Facon

TPS8056Background: DARA is a human, anti-CD38 IgGκ monoclonal antibody that significantly reduced the risk of progression/death with a manageable safety profile across several phase 3 studies in re...

Keywords:

Oncology
Daratumumab
Dexamethasone
Pathology
Internal medicine
Medicine
Dara
Monoclonal antibody
Multiple myeloma
Bortezomib/lenalidomide
initial therapy
in patient
newly diagnosed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations